奥他卡因 | 13912-77-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 奥他卡因
• 中文别名: 乙丁胺卡因；辛卡因
• 英文名称: lidocaine
• 英文别名: 3-diethylamino-butyric acid anilide；3-Diaethylamino-buttersaeure-anilid；octacaine；3-(diethylamino)-N-phenylbutanamide
• CAS: 13912-77-1
• 化学式: C₁₄H₂₂N₂O
• 分子量: 234.341
• InChiKey: HKOURKRGAFKVFP-UHFFFAOYSA-N

物化性质

• 熔点：
  46-47°
• 沸点：
  bp1 200°
• 密度：
  1.022±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）
• 保留指数：
  1893

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为产物：
  描述：

  3-ethylaminobut-2-enoic acid phenylamide 在 甲醇 、 钯 作用下， 生成 奥他卡因
  参考文献：
  名称：

  DE967642

  摘要：

  公开号：

文献信息

• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。
• Über die Herstellung und physiologischen Eigenschaften einiger Acetylenverbindungen und verwandter Stoffe. 1. Mitteilung
  作者：Emil Hofstetter、A. E. Wilder Smith

  DOI：10.1002/hlca.19530360704

  日期：——

  The preparation of 3-p-methoxyphenyl-1-pentyne-3-ol,3-p-methoxyphenyl-2-pentene-4-yne, 3,4-bis(p-methoxyphenyl)-1-hexyne-3-ol, some reaction products and the physiological properties of these substances are described. 3,4-Bis(p-methoxyphenyl)-hexyne-ol is practically non-toxic and possesses sedative properties.

  3-对甲氧基苯基-1-戊炔-3-醇，3-对甲氧基苯基-2-戊烯-4-炔，3,4-双（对甲氧基苯基）-1-己炔-3-醇的制备描述了这些物质的一些反应产物和生理特性。3，4-双（对甲氧基苯基）-己炔醇实际上是无毒的，并具有镇静作用。
• Crosslinked hyaluronic acid compositions for tissue augmentation
  申请人：Sadozai K. Khalid

  公开号：US20050136122A1

  公开（公告）日：2005-06-23

  A hyaluronic acid (HA) composition includes crosslinked, water-insoluble, hydrated HA gel particles. The HA includes crosslinks represented by the following structural formula: HA—U—R 2 —U—HA The variables are defined herein. A method of augmenting tissue in a subject includes inserting a needle into a subject at a location in the subject that is in need of tissue augmentation, wherein the needle is coupled to a syringe loaded with the HA composition, and applying force to the syringe, to deliver the HA composition into the subject. A method of preparing the HA composition, includes forming water-insoluble, dehydrated crosslinked HA particles, separating the water-insoluble, dehydrated particles by average diameter, selecting a subset of particles by average diameter, and hydrating the subset of dehydrated particles with a physiologically compatible aqueous solution. Another method of preparing the crosslinked HA composition includes crosslinking a precursor of the crosslinked HA with a biscarbodiimide in the presence of a pH buffer and dehydrating the crosslinked HA. Also included is a method of augmenting tissue in a subject that is in need of tissue augmentation. A method of stabilizing crosslinked HA includes hydrating water-insoluble, dehydrated crosslinked HA with a physiologically compatible aqueous solution that includes a local anesthetic, wherein the value of storage modulus G′ for the stabilized composition is at least about 110% of the value of G′ for a non-stabilized composition,. Also included is the stabilized HA composition.

  一种透明质酸（HA）组合物包括交联的、不溶于水的、水合的HA凝胶颗粒。HA包括由以下结构式表示的交联：HA—U—R2—U—HA。变量在此定义。一种在受试者中增强组织的方法包括将针插入受试者体内需要组织增强的位置，其中针连接到装有HA组合物的注射器，并施加力量到注射器，将HA组合物注入受试者体内。一种制备HA组合物的方法包括形成不溶于水的、脱水的交联HA颗粒，通过平均直径分离不溶于水的、脱水的颗粒，通过平均直径选择颗粒的子集，并用生理兼容的水溶液使脱水的颗粒子集水化。另一种制备交联HA组合物的方法包括在pH缓冲剂存在下用双异氰酸酯交联交联HA的前体，并脱水交联HA。还包括一种在需要组织增强的受试者中增强组织的方法。一种稳定交联HA的方法包括用含有局部麻醉剂的生理兼容水溶液水化不溶于水的、脱水的交联HA，其中稳定组合物的存储模量G′的值至少为非稳定组合物G′值的约110%。还包括稳定的HA组合物。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• Analgesics, anaesthetics, antifoulants, aversants, irritants, incapacitants and compositions containing the same
  申请人：Blum Mel

  公开号：US20070225515A1

  公开（公告）日：2007-09-27

  Compounds and compositions the same. Method of making the compounds. The compounds and/or compositions used as an analgesic, anaesthetic, antifoulant, aversant, irritant, sternutator, neurodegenerator, counter irritant (delayed), rubifaciant, stomachic, fungicide, insecticide, preservative, circulatory stimulant, cardio-protective agent, immune booster, decongestant, anti-inflammatory agent, incapacitant, biocide, mildewcide, pharmaceutical, repellent, flavorant, carminative, antismoking agent, and/or antithrombotic agent. One of the compounds being lidocaine nonivamide. The compositions comprising one or more of: the compounds, one or more of an antioxidant, a UV absorber, and one or more biocides such as, for example, OBPA.

  化合物和组合物相同。制备这些化合物的方法。这些化合物和/或组合物用作止痛剂、麻醉剂、防污剂、驱避剂、刺激剂、喷鼻剂、神经变性剂、延迟性刺激剂、红斑剂、胃药、杀真菌剂、杀虫剂、防腐剂、循环刺激剂、心脏保护剂、免疫增强剂、通窍剂、抗炎剂、致残剂、生物杀灭剂、霉菌杀灭剂、药用、驱虫剂、调味剂、驱风剂、抗吸烟剂和/或抗血栓剂。其中一种化合物是利多卡因辛烷酸酯。组合物包括：这些化合物中的一种或多种、一种或多种抗氧化剂、一种或多种紫外线吸收剂，以及一种或多种生物杀灭剂，例如OBPA。

表征谱图